CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cellsGianluca Storci, Francesca Bonifazi, Francesco De Felice et al.|Journal of Clinical Investigation|2024Cited by 28
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experienceAlessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani et al.|American Journal of Hematology|2021Cited by 17
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone LymphomaCamilla Mazzoni, Pier Luigi Zinzani, Gabriele Gugliotta et al.|European Journal Of Haematology|2024Cited by 3
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practiceCinzia Pellegrini, Pier Luigi Zinzani, Beatrice Casadei et al.|Annals of Hematology|2025Cited by 2
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world studyBeatrice Casadei, Pier Luigi Zinzani, Lisa Argnani et al.|Blood Advances|2025Cited by 2